Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

John L. Neumeyer, PH.D.

TitleLecturer on Psychiatry
InstitutionMcLean Hospital
DepartmentPsychiatry
AddressMclean Hospital
Adarc/Oaks Bldg
115 Mill St
Belmont MA 02478
Phone617/855-3388
Fax617/855-2519

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Neumeyer JL, Zhang B, Zhang T, Sromek AW, Knapp BI, Cohen DJ, Bidlack JM. Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors. J Med Chem. 2012 Apr 26; 55(8):3878-90.
    View in: PubMed
  2. Neumeyer JL. A tribute to Joseph G. Cannon, 1926-2011. J Med Chem. 2012 Feb 23; 55(4):1423.
    View in: PubMed
  3. Zhang B, Zhang T, Sromek AW, Scrimale T, Bidlack JM, Neumeyer JL. Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for ?, µ, and d opioid receptors. Bioorg Med Chem. 2011 May 1; 19(9):2808-16.
    View in: PubMed
  4. Zhang T, Yan Z, Sromek A, Knapp BI, Scrimale T, Bidlack JM, Neumeyer JL. Aminothiazolomorphinans with mixed ? and µ opioid activity. J Med Chem. 2011 Mar 24; 54(6):1903-13.
    View in: PubMed
  5. Balboni G, Salvadori S, Marczak ED, Knapp BI, Bidlack JM, Lazarus LH, Peng X, Si YG, Neumeyer JL. Opioid bifunctional ligands from morphine and the opioid pharmacophore Dmt-Tic. Eur J Med Chem. 2011 Feb; 46(2):799-803.
    View in: PubMed
  6. SUN JF, WANG YH, LI FY, LU G, TAO YM, CHENG Y, CHEN J, XU XJ, CHI ZQ, NEUMEYER JL, ZHANG A, LIU JG. Effects of ATPM-ET, a novel ? agonist with partial µ activity, on physical dependence and behavior sensitization in mice. Acta Pharmacol Sin. 2010 Dec; 31(12):1547-52.
    View in: PubMed
  7. Fulton BS, Knapp BL, Bidlack JM, Neumeyer JL. Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorg Med Chem Lett. 2010 Mar 1; 20(5):1507-9.
    View in: PubMed
  8. Decker M, Si YG, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14; 53(1):402-18.
    View in: PubMed
  9. Decker M, Fulton BS, Zhang B, Knapp BI, Bidlack JM, Neumeyer JL. Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands. J Med Chem. 2009 Dec 10; 52(23):7389-96.
    View in: PubMed
  10. Chen XQ, Zhang J, Neumeyer JL, Jin GZ, Hu GY, Zhang A, Zhen X. Arylbenzazepines are potent modulators for the delayed rectifier K+ channel: a potential mechanism for their neuroprotective effects. PLoS One. 2009; 4(6):e5811.
    View in: PubMed
  11. Wang YJ, Tao YM, Li FY, Wang YH, Xu XJ, Chen J, Cao YL, Chi ZQ, Neumeyer JL, Zhang A, Liu JG. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior. J Pharmacol Exp Ther. 2009 Apr; 329(1):306-13.
    View in: PubMed
  12. Si YG, Choi YK, Gardner MP, Tarazi FI, Baldessarini RJ, Neumeyer JL. Synthesis and neuropharmacological evaluation of esters of R(-)-N-alkyl-11-hydroxy-2-methoxynoraporphines. Bioorg Med Chem Lett. 2009 Jan 1; 19(1):51-3.
    View in: PubMed
  13. Fulton BS, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors. Bioorg Med Chem Lett. 2008 Aug 15; 18(16):4474-6.
    View in: PubMed
  14. Si YG, Gardner MP, Tarazi FI, Baldessarini RJ, Neumeyer JL. Synthesis and binding studies of 2-O- and 11-O-substituted N-alkylnoraporphines. Bioorg Med Chem Lett. 2008 Jul 15; 18(14):3971-3.
    View in: PubMed
  15. Mathews JL, Fulton BS, Negus SS, Neumeyer JL, Bidlack JM. In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties. Neurochem Res. 2008 Oct; 33(10):2142-50.
    View in: PubMed
  16. Si YG, Gardner MP, Tarazi FI, Baldessarini RJ, Neumeyer JL. Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity. J Med Chem. 2008 Feb 28; 51(4):983-7.
    View in: PubMed
  17. Reindl JD, Rowan K, Carey AN, Peng X, Neumeyer JL, McLaughlin JP. Antidepressant-like effects of the novel kappa opioid antagonist MCL-144B in the forced-swim test. Pharmacology. 2008; 81(3):229-35.
    View in: PubMed
  18. Desai RI, Neumeyer JL, Bergman J, Paronis CA. Pharmacological characterization of the effects of dopamine D(1) agonists on eye blinking in rats. Behav Pharmacol. 2007 Dec; 18(8):745-54.
    View in: PubMed
  19. Si YG, Gardner MP, Tarazi FI, Baldessarini RJ, Neumeyer JL. R-(-)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT1A receptor ligands. Bioorg Med Chem Lett. 2007 Aug 1; 17(15):4128-30.
    View in: PubMed
  20. Zhang A, Li F, Ding C, Yao Q, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and pharmacological evaluation of 6,7-indolo/thiazolo-morphinans--further SAR of levorphanol. J Med Chem. 2007 May 31; 50(11):2747-51.
    View in: PubMed
  21. Wuest F, Berndt M, Strobel K, van den Hoff J, Peng X, Neumeyer JL, Bergmann R. Synthesis and radiopharmacological characterization of 2beta-carbo-2'-[18F]fluoroethoxy-3beta-(4-bromo-phenyl)tropane ([18F]MCL-322) as a PET radiotracer for imaging the dopamine transporter (DAT). Bioorg Med Chem. 2007 Jul 1; 15(13):4511-9.
    View in: PubMed
  22. Peng X, Knapp BI, Bidlack JM, Neumeyer JL. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors. J Med Chem. 2007 May 3; 50(9):2254-8.
    View in: PubMed
  23. Peng X, Knapp BI, Bidlack JM, Neumeyer JL. In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15; 15(12):4106-12.
    View in: PubMed
  24. Zhang A, Zhang Y, Branfman AR, Baldessarini RJ, Neumeyer JL. Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25; 50(2):171-81.
    View in: PubMed
  25. Peng X, Knapp BI, Bidlack JM, Neumeyer JL. High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15; 17(6):1508-11.
    View in: PubMed
  26. Zhang A, Neumeyer JL, Baldessarini RJ. Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders. Chem Rev. 2007 Jan; 107(1):274-302.
    View in: PubMed
  27. Peng X, Neumeyer JL. Kappa receptor bivalent ligands. Curr Top Med Chem. 2007; 7(4):363-73.
    View in: PubMed
  28. Desai RI, Neumeyer JL, Paronis CA, Nguyen P, Bergman J. Behavioral effects of the R-(+)- and S-(-)-enantiomers of the dopamine D(1)-like partial receptor agonist SKF 83959 in monkeys. Eur J Pharmacol. 2007 Mar 8; 558(1-3):98-106.
    View in: PubMed
  29. Neumeyer JL, Peng X, Knapp BI, Bidlack JM, Lazarus LH, Salvadori S, Trapella C, Balboni G. New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem. 2006 Sep 7; 49(18):5640-3.
    View in: PubMed
  30. Peng X, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors. J Med Chem. 2006 Jan 12; 49(1):256-62.
    View in: PubMed
  31. Tóth M, Berényi S, Csutorás C, Kula NS, Zhang K, Baldessarini RJ, Neumeyer JL. Synthesis and dopamine receptor binding of sulfur-containing aporphines. Bioorg Med Chem. 2006 Mar 15; 14(6):1918-23.
    View in: PubMed
  32. Mathews JL, Peng X, Xiong W, Zhang A, Negus SS, Neumeyer JL, Bidlack JM. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties. J Pharmacol Exp Ther. 2005 Nov; 315(2):821-7.
    View in: PubMed
  33. Zhang A, Csutoras C, Zong R, Neumeyer JL. Synthesis of 2-fluoro-11-hydroxy-N-propylnoraporphine: a potential dopamine D2 agonist. Org Lett. 2005 Jul 21; 7(15):3239-42.
    View in: PubMed
  34. Finnema SJ, Seneca N, Farde L, Shchukin E, Sóvágó J, Gulyás B, Wikström HV, Innis RB, Neumeyer JL, Halldin C. A preliminary PET evaluation of the new dopamine D2 receptor agonist [11C]MNPA in cynomolgus monkey. Nucl Med Biol. 2005 May; 32(4):353-60.
    View in: PubMed
  35. Peng X, Zhang A, Kula NS, Baldessarini RJ, Neumeyer JL. Synthesis and amine transporter affinities of novel phenyltropane derivatives as potential positron emission tomography (PET) imaging agents. Bioorg Med Chem Lett. 2004 Nov 15; 14(22):5635-9.
    View in: PubMed
  36. Csutoras C, Zhang A, Zhang K, Kula NS, Baldessarini RJ, Neumeyer JL. Synthesis and neuropharmacological evaluation of R(-)-N-alkyl-11-hydroxynoraporphines and their esters. Bioorg Med Chem. 2004 Jul 1; 12(13):3553-9.
    View in: PubMed
  37. Csutoras C, Zhang A, Bidlack JM, Neumeyer JL. An investigation of the N-demethylation of 3-deoxymorphine and the affinity of the alkylation products to mu, delta, and kappa receptors. Bioorg Med Chem. 2004 May 15; 12(10):2687-90.
    View in: PubMed
  38. Zhang A, Xiong W, Hilbert JE, DeVita EK, Bidlack JM, Neumeyer JL. 2-aminothiazole-derived opioids. Bioisosteric replacement of phenols. J Med Chem. 2004 Apr 8; 47(8):1886-8.
    View in: PubMed
  39. Chaly T, Baldwin RM, Neumeyer JL, Hellman MJ, Dhawan V, Garg PK, Tamagnan G, Staley JK, Al-Tikriti MS, Hou Y, Zoghbi SS, Gu XH, Zong R, Eidelberg D. Radiosynthesis of [18F] N-(3-Fluoropropyl)-2-beta-Carbomethoxy-3-beta-(4-Bromophenyl) Nortropane and the regional brain uptake in non human primate using PET. Nucl Med Biol. 2004 Jan; 31(1):125-31.
    View in: PubMed
  40. Zhang A, Xiong W, Bidlack JM, Hilbert JE, Knapp BI, Wentland MP, Neumeyer JL. 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors. J Med Chem. 2004 Jan 1; 47(1):165-74.
    View in: PubMed
  41. Neumeyer JL, Zhang A, Xiong W, Gu XH, Hilbert JE, Knapp BI, Negus SS, Mello NK, Bidlack JM. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors. J Med Chem. 2003 Nov 20; 46(24):5162-70.
    View in: PubMed
  42. Neumeyer JL, Kula NS, Bergman J, Baldessarini RJ. Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines. Eur J Pharmacol. 2003 Aug 8; 474(2-3):137-40.
    View in: PubMed
  43. Bowen CA, Negus SS, Zong R, Neumeyer JL, Bidlack JM, Mello NK. Effects of mixed-action kappa/mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys. Neuropsychopharmacology. 2003 Jun; 28(6):1125-39.
    View in: PubMed
  44. Zhang A, Neumeyer JL. Microwave-promoted Pd-catalyzed cyanation of aryl triflates: a fast and versatile access to 3-cyano-3-desoxy-10-ketomorphinans. Org Lett. 2003 Jan 23; 5(2):201-3.
    View in: PubMed
  45. Gu XH, Zong R, Kula NS, Baldessarini RJ, Neumeyer JL. Synthesis and biological evaluation of a series of novel N- or O-fluoroalkyl derivatives of tropane: potential positron emission tomography (PET) imaging agents for the dopamine transporter. Bioorg Med Chem Lett. 2001 Dec 3; 11(23):3049-53.
    View in: PubMed
  46. Neumeyer JL, Gu XH, van Vliet LA, DeNunzio NJ, Rusovici DE, Cohen DJ, Negus SS, Mello NK, Bidlack JM. Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan. Bioorg Med Chem Lett. 2001 Oct 22; 11(20):2735-40.
    View in: PubMed
  47. Neumeyer JL, Mello NK, Negus SS, Bidlack JM. Kappa opioid agonists as targets for pharmacotherapies in cocaine abuse. Pharm Acta Helv. 2000 Mar; 74(2-3):337-44.
    View in: PubMed
  48. Neumeyer JL, Bidlack JM, Zong R, Bakthavachalam V, Gao P, Cohen DJ, Negus SS, Mello NK. Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence. J Med Chem. 2000 Jan 13; 43(1):114-22.
    View in: PubMed
  49. Scanley BE, Gandelman MS, Laruelle M, Al-Tikriti MS, Baldwin RM, Zoghbi SS, Hoffer PB, Wang S, Neumeyer JL, Innis RB. [123I]IPCIT and [123I]beta-CIT as SPECT tracers for the dopamine transporter: a comparative analysis in nonhuman primates. Nucl Med Biol. 2000 Jan; 27(1):13-21.
    View in: PubMed
  50. Kula NS, Baldessarini RJ, Tarazi FI, Fisser R, Wang S, Trometer J, Neumeyer JL. [3H]beta-CIT: a radioligand for dopamine transporters in rat brain tissue. Eur J Pharmacol. 1999 Dec 3; 385(2-3):291-4.
    View in: PubMed
  51. Zhang K, Tarazi FI, Kula NS, Baldessarini RJ, Neumeyer JL. Selective alkylatation of dopamine D2 and D4 receptors in rat brain by N-(p-isothiocyanatophenethyl)spiperone. Neurosci Lett. 1999 Oct 29; 274(3):155-8.
    View in: PubMed
  52. Tamagnan G, Gao Y, Xu L, Kula NS, Baldessarini RJ, Neumeyer JL. Nonisotopic surrogates for technetium as ligands for monoamine transporters. Adv Neurol. 1999; 80:99-103.
    View in: PubMed
  53. Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, Neumeyer J, Eidelberg D. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med. 1998 Sep; 39(9):1521-30.
    View in: PubMed
  54. Yeghiayan SK, Gongwer MA, Baldessarini RJ, Kula NS, Zong R, Neumeyer JL. Local injection of alkylating and nonalkylating dopamine receptor antagonists into rat basal forebrain: autoradiographic assessment of D2-like and D3 sites. Brain Res. 1998 May 11; 792(2):324-6.
    View in: PubMed
  55. Tarazi FI, Yeghiayan SK, Neumeyer JL, Baldessarini RJ. Medial prefrontal cortical D2 and striatolimbic D4 dopamine receptors: common targets for typical and atypical antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry. 1998 May; 22(4):693-707.
    View in: PubMed
  56. Abi-Dargham A, Innis RB, Wisniewski G, Baldwin RM, Neumeyer JL, Seibyl JP. Human biodistribution and dosimetry of iodine-123-fluoroalkyl analogs of beta-CIT. Eur J Nucl Med. 1997 Nov; 24(11):1422-5.
    View in: PubMed
  57. Tarazi FI, Yeghiayan SK, Baldessarini RJ, Kula NS, Neumeyer JL. Long-term effects of S(+)N-n-propylnorapomorphine compared with typical and atypical antipsychotics: differential increases of cerebrocortical D2-like and striatolimbic D4-like dopamine receptors. Neuropsychopharmacology. 1997 Sep; 17(3):186-96.
    View in: PubMed
  58. Oliver DW, Dormehl IC, Van der Schyf CJ, Neumeyer JL, Hugo N, Keeve R, Rossouw NT, Müller-Gärtner HW, Castagnoli N. Effect of the haloperidol tetrahydropyridine metabolite 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6- tetrahydropyridine on dopamine receptor and transporter binding. A nonhuman primate 123I-iodobenzamide and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane single photon emission computed tomographic study. Arzneimittelforschung. 1997 Jun; 47(6):692-9.
    View in: PubMed
  59. Chaly T, Dhawan V, Kazumata K, Antonini A, Margouleff C, Dahl JR, Belakhlef A, Margouleff D, Yee A, Wang S, Tamagnan G, Neumeyer JL, Eidelberg D. Radiosynthesis of [18F] N-3-fluoropropyl-2-beta-carbomethoxy-3-beta-(4-iodophenyl) nortropane and the first human study with positron emission tomography. Nucl Med Biol. 1996 Nov; 23(8):999-1004.
    View in: PubMed
  60. Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, Margouleff C, Babchyck B, Zanzi I, Eidelberg D. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med. 1996 Nov; 37(11):1760-5.
    View in: PubMed
  61. Abi-Dargham A, Gandelman MS, DeErausquin GA, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Laruelle M, Charney DS, Hoffer PB, Neumeyer JL, Innis RB. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med. 1996 Jul; 37(7):1129-33.
    View in: PubMed
  62. Mak CK, Avalos M, Randall PK, Kwan SW, Abell CW, Neumeyer JL, Whisennand R, Wilcox RE. Improved models for pharmacological null experiments: calculation of drug efficacy at recombinant D1A dopamine receptors stably expressed in clonal cell lines. Neuropharmacology. 1996 May; 35(5):549-70.
    View in: PubMed
  63. Seibyl JP, Laruelle M, van Dyck CH, Wallace E, Baldwin RM, Zoghbi S, Zea-Ponce Y, Neumeyer JL, Charney DS, Hoffer PB, Innis RB. Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters. J Nucl Med. 1996 Feb; 37(2):222-8.
    View in: PubMed
  64. Neumeyer JL, Tamagnan G, Wang S, Gao Y, Milius RA, Kula NS, Baldessarini RJ. N-substituted analogs of 2 beta-carbomethoxy-3 beta- (4'-iodophenyl)tropane (beta-CIT) with selective affinity to dopamine or serotonin transporters in rat forebrain. J Med Chem. 1996 Jan 19; 39(2):543-8.
    View in: PubMed
  65. Lanier B, Raddatz R, Bakthavachalam V, Coupry I, Neumeyer JL, Lanier SM. Structural and ligand recognition properties of imidazoline binding proteins in tissues of rat and rabbit. Mol Pharmacol. 1995 Oct; 48(4):703-10.
    View in: PubMed
  66. Lundkvist C, Halldin C, Swahn CG, Hall H, Karlsson P, Nakashima Y, Wang S, Milius RA, Neumeyer JL, Farde L. [O-methyl-11C]beta-CIT-FP, a potential radioligand for quantitation of the dopamine transporter: preparation, autoradiography, metabolite studies, and positron emission tomography examinations. Nucl Med Biol. 1995 Oct; 22(7):905-13.
    View in: PubMed
  67. Lanier SM, Lanier B, Bakthavachalam V, McGrath CR, Neumeyer JL. Use of high affinity, radioiodinated probes for identification of imidazoline/guanidinium receptive sites. Ann N Y Acad Sci. 1995 Jul 12; 763:106-11.
    View in: PubMed
  68. Kuikka JT, Akerman K, Bergström KA, Karhu J, Hiltunen J, Haukka J, Heikkinen J, Tiihonen J, Wang S, Neumeyer JL. Iodine-123 labelled N-(2-fluoroethyl)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)nortropane for dopamine transporter imaging in the living human brain. Eur J Nucl Med. 1995 Jul; 22(7):682-6.
    View in: PubMed
  69. Kuikka JT, Bergström KA, Ahonen A, Hiltunen J, Haukka J, Länsimies E, Wang S, Neumeyer JL. Comparison of iodine-123 labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)-N-(3-fluoropropyl)nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med. 1995 Apr; 22(4):356-60.
    View in: PubMed
  70. Zea-Ponce Y, Baldwin RM, Laruelle M, Wang S, Neumeyer JL, Innis RB. Simplified multidose preparation of iodine-123-beta-CIT: a marker for dopamine transporters. J Nucl Med. 1995 Mar; 36(3):525-9.
    View in: PubMed
  71. Baldwin RM, Zea-Ponce Y, al-Tikriti MS, Zoghbi SS, Seibyl JP, Charney DS, Hoffer PB, Wang S, Milius RA, Neumeyer JL, et al. Regional brain uptake and pharmacokinetics of [123I]N-omega-fluoroalkyl-2 beta-carboxy-3 beta-(4-iodophenyl)nortropane esters in baboons. Nucl Med Biol. 1995 Feb; 22(2):211-9.
    View in: PubMed
  72. Laruelle M, Wallace E, Seibyl JP, Baldwin RM, Zea-Ponce Y, Zoghbi SS, Neumeyer JL, Charney DS, Hoffer PB, Innis RB. Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab. 1994 Nov; 14(6):982-94.
    View in: PubMed
  73. Baldessarini RJ, Campbell A, Ben-Jonathan N, Ellingboe J, Zong R, Neumeyer JL. Effects of aporphine isomers on rat prolactin. Neurosci Lett. 1994 Aug 1; 176(2):269-71.
    View in: PubMed
  74. Ivkovic B, Bakthavachalam V, Zhang W, Parini A, Diz D, Bosch S, Neumeyer JL, Lanier SM. Development of a high-affinity radioiodinated ligand for identification of imidazoline/guanidinium receptive sites (IGRS): intratissue distribution of IGRS in liver, forebrain, and kidney. Mol Pharmacol. 1994 Jul; 46(1):15-23.
    View in: PubMed
  75. Neumeyer JL, Wang S, Gao Y, Milius RA, Kula NS, Campbell A, Baldessarini RJ, Zea-Ponce Y, Baldwin RM, Innis RB. N-omega-fluoroalkyl analogs of (1R)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)-tropane (beta-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem. 1994 May 27; 37(11):1558-61.
    View in: PubMed
  76. Seibyl JP, Wallace E, Smith EO, Stabin M, Baldwin RM, Zoghbi S, Zea-Ponce Y, Gao Y, Zhang WY, Neumeyer JL, et al. Whole-body biodistribution, radiation absorbed dose and brain SPECT imaging with iodine-123-beta-CIT in healthy human subjects. J Nucl Med. 1994 May; 35(5):764-70.
    View in: PubMed
  77. Kula NS, Baldessarini RJ, Kebabian JW, Neumeyer JL. S-(+)-aporphines are not selective for human D3 dopamine receptors. Cell Mol Neurobiol. 1994 Apr; 14(2):185-91.
    View in: PubMed
  78. Baldessarini RJ, Kula NS, Zong R, Neumeyer JL. Receptor affinities of aporphine enantiomers in rat brain tissue. Eur J Pharmacol. 1994 Mar 11; 254(1-2):199-203.
    View in: PubMed
  79. Laruelle M, Giddings SS, Zea-Ponce Y, Charney DS, Neumeyer JL, Baldwin RM, Innis RB. Methyl 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylate in vitro binding to dopamine and serotonin transporters under "physiological" conditions. J Neurochem. 1994 Mar; 62(3):978-86.
    View in: PubMed
  80. Hashimoto K, Mantione CR, Spada MR, Neumeyer JL, London ED. Further characterization of [3H]ifenprodil binding in rat brain. Eur J Pharmacol. 1994 Jan 1; 266(1):67-77.
    View in: PubMed
  81. Jacobson KA, Shi D, Gallo-Rodriguez C, Manning M, Müller C, Daly JW, Neumeyer JL, Kiriasis L, Pfleiderer W. Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors. J Med Chem. 1993 Sep 3; 36(18):2639-44.
    View in: PubMed
  82. Baldessarini RJ, Kula NS, McGrath CR, Bakthavachalam V, Kebabian JW, Neumeyer JL. Isomeric selectivity at dopamine D3 receptors. Eur J Pharmacol. 1993 Aug 3; 239(1-3):269-70.
    View in: PubMed
  83. Lanier SM, Ivkovic B, Singh I, Neumeyer JL, Bakthavachalam V. Visualization of multiple imidazoline/guanidinium-receptive sites. J Biol Chem. 1993 Jul 25; 268(21):16047-51.
    View in: PubMed
  84. Baldwin RM, Zea-Ponce Y, Zoghbi SS, Laurelle M, al-Tikriti MS, Sybirska EH, Malison RT, Neumeyer JL, Milius RA, Wang S, et al. Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. Nucl Med Biol. 1993 Jul; 20(5):597-606.
    View in: PubMed
  85. Wang S, Gao Y, Laruelle M, Baldwin RM, Scanley BE, Innis RB, Neumeyer JL. Enantioselectivity of cocaine recognition sites: binding of (1S)- and (1R)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane (beta-CIT) to monoamine transporters. J Med Chem. 1993 Jun 25; 36(13):1914-7.
    View in: PubMed
  86. Müller L, Halldin C, Farde L, Karlsson P, Hall H, Swahn CG, Neumeyer J, Gao Y, Milius R. [11C] beta-CIT, a cocaine analogue. Preparation, autoradiography and preliminary PET investigations. Nucl Med Biol. 1993 Apr; 20(3):249-55.
    View in: PubMed
  87. Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, al-Tikriti MS, Sybirska EH, Zimmermann RC, Wisniewski G, Neumeyer JL, et al. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse. 1993 Apr; 13(4):295-309.
    View in: PubMed
  88. Campbell A, Baldessarini RJ, Neumeyer JL. Altered spontaneous behavior and sensitivity to apomorphine in rats following pretreatment with S(+)-aporphines or fluphenazine. Psychopharmacology (Berl). 1993; 111(3):351-8.
    View in: PubMed
  89. Baldessarini RJ, Kula NS, Campbell A, Bakthavachalam V, Yuan J, Neumeyer JL. Prolonged D2 antidopaminergic activity of alkylating and nonalkylating derivatives of spiperone in rat brain. Mol Pharmacol. 1992 Nov; 42(5):856-63.
    View in: PubMed
  90. Neumeyer JL, Kula NS, Baldessarini RJ, Baindur N. Stereoisomeric probes for the D1 dopamine receptor: synthesis and characterization of R-(+) and S-(-) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analogue. J Med Chem. 1992 Apr 17; 35(8):1466-71.
    View in: PubMed
  91. Neumeyer JL, Baindur N, Bakthavachalam V, Yuan J, Madras BK, Kula NS, Campbell A, Baldessarini RJ. Alan Horn Memorial Lecture. Selective probes for characterization of dopamine D1 and D2 receptors. Neurochem Int. 1992 Mar; 20 Suppl:63S-68S.
    View in: PubMed
  92. Baindur N, Tran M, Niznik HB, Guan HC, Seeman P, Neumeyer JL. (+/-)-3-allyl-7-halo-8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines as selective high affinity D1 dopamine receptor antagonists: synthesis and structure-activity relationship. J Med Chem. 1992 Jan; 35(1):67-72.
    View in: PubMed
  93. Neumeyer JL, Baindur N, Niznik HB, Guan HC, Seeman P. (+/-)-3-Allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepin, a new high-affinity D1 dopamine receptor ligand: synthesis and structure-activity relationship. J Med Chem. 1991 Dec; 34(12):3366-71.
    View in: PubMed
  94. Bakthavachalam V, Baindur N, Madras BK, Neumeyer JL. Fluorescent probes for dopamine receptors: synthesis and characterization of fluorescein and 7-nitrobenz-2-oxa-1,3-diazol-4-yl conjugates of D-1 and D-2 receptor ligands. J Med Chem. 1991 Nov; 34(11):3235-41.
    View in: PubMed
  95. Neumeyer JL, Wang SY, Milius RA, Baldwin RM, Zea-Ponce Y, Hoffer PB, Sybirska E, al-Tikriti M, Charney DS, Malison RT, et al. [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem. 1991 Oct; 34(10):3144-6.
    View in: PubMed
  96. Milius RA, Saha JK, Madras BK, Neumeyer JL. Synthesis and receptor binding of N-substituted tropane derivatives. High-affinity ligands for the cocaine receptor. J Med Chem. 1991 May; 34(5):1728-31.
    View in: PubMed
  97. Baldessarini RJ, Kula NS, Gao Y, Campbell A, Neumeyer JL. R(-)2-fluoro-N-n-propylnorapomorphine: a very potent and D2-selective dopamine agonist. Neuropharmacology. 1991 Jan; 30(1):97-9.
    View in: PubMed
  98. Campbell A, Yeghiayan S, Baldessarini RJ, Neumeyer JL. Selective antidopaminergic effects of S(+)N-n-propylnoraporphines in limbic versus extrapyramidal sites in rat brain: comparisons with typical and atypical antipsychotic agents. Psychopharmacology (Berl). 1991; 103(3):323-9.
    View in: PubMed
  99. Neumeyer JL, Gao YG, Kula NS, Baldessarini RJ. R and S enantiomers of 11-hydroxy- and 10,11-dihydroxy-N-allylnoraporphine: synthesis and affinity for dopamine receptors in rat brain tissue. J Med Chem. 1991 Jan; 34(1):24-8.
    View in: PubMed
  100. Neumeyer JL, Gao YG, Kula NS, Baldessarini RJ. Synthesis and dopamine receptor affinity of (R)-(-)-2-fluoro-N-n-propylnorapomorphine: a highly potent and selective dopamine D2 agonist. J Med Chem. 1990 Dec; 33(12):3122-4.
    View in: PubMed
  101. Baldessarini RJ, Marsh ER, Kula NS, Zong RS, Gao YG, Neumeyer JL. Effects of isomers of hydroxyaporphines on dopamine metabolism in rat brain regions. Biochem Pharmacol. 1990 Aug 1; 40(3):417-23.
    View in: PubMed
  102. Booth RG, Baldessarini RJ, Kula NS, Gao Y, Zong R, Neumeyer JL. Presynaptic inhibition of dopamine synthesis in rat striatal tissue by enantiomeric mono- and dihydroxyaporphines. Mol Pharmacol. 1990 Jul; 38(1):92-101.
    View in: PubMed
  103. Madras BK, Canfield DR, Pfaelzer C, Vittimberga FJ, Difiglia M, Aronin N, Bakthavachalam V, Baindur N, Neumeyer JL. Fluorescent and biotin probes for dopamine receptors: D1 and D2 receptor affinity and selectivity. Mol Pharmacol. 1990 Jun; 37(6):833-9.
    View in: PubMed
  104. Campbell A, Baldessarini RJ, Gao Y, Zong R, Neumeyer JL. R(-) and S(+) stereoisomers of 11-hydroxy- and 11-methoxy-N-n-propylnoraporphine: central dopaminergic behavioral activity in the rat. Neuropharmacology. 1990 Jun; 29(6):527-36.
    View in: PubMed
  105. Gao YG, Baldessarini RJ, Kula NS, Neumeyer JL. Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues. J Med Chem. 1990 Jun; 33(6):1800-5.
    View in: PubMed
  106. Madras BK, Kamien JB, Fahey MA, Canfield DR, Milius RA, Saha JK, Neumeyer JL, Spealman RD. N-modified fluorophenyltropane analogs of cocaine with high affinity for cocaine receptors. Pharmacol Biochem Behav. 1990 Apr; 35(4):949-53.
    View in: PubMed
  107. Neumeyer JL, Baindur N, Yuan J, Booth G, Seeman P, Niznik HB. Development of a high affinity and stereoselective photoaffinity label for the D-1 dopamine receptor: synthesis and resolution of 7-[125I]iodo-8-hydroxy-3-methyl-1-(4'-azidophenyl)-2,3,4,5-tetrahydro- 1H-3-benzazepine. J Med Chem. 1990 Feb; 33(2):521-6.
    View in: PubMed
  108. Gao YG, Ram VJ, Campbell A, Kula NS, Baldessarini RJ, Neumeyer JL. Synthesis and structural requirements of N-substituted norapomorphines for affinity and activity at dopamine D-1, D-2, and agonist receptor sites in rat brain. J Med Chem. 1990 Jan; 33(1):39-44.
    View in: PubMed
  109. Madras BK, Spealman RD, Fahey MA, Neumeyer JL, Saha JK, Milius RA. Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane. Mol Pharmacol. 1989 Oct; 36(4):518-24.
    View in: PubMed
  110. Jacobson KA, Kiriasis L, Barone S, Bradbury BJ, Kammula U, Campagne JM, Secunda S, Daly JW, Neumeyer JL, Pfleiderer W. Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors. J Med Chem. 1989 Aug; 32(8):1873-9.
    View in: PubMed
  111. Ramsby S, Neumeyer JL, Grigoriadis D, Seeman P. 2-Haloaporphines as potent dopamine agonists. J Med Chem. 1989 Jun; 32(6):1198-201.
    View in: PubMed
  112. Trainor TM, Vouros P, Lampen P, Neumeyer JL, Baldessarini RJ, Kula NS. Determination of N-n-propylnorapomorphine in serum and brain tissue by gas chromatography-negative ion chemical ionization mass spectrometry. J Chromatogr. 1988 Dec 21; 457:257-66.
    View in: PubMed
  113. Baindur N, Neumeyer JL, Niznik HB, Bzowej NH, Jarvie KR, Seeman P, Garlick RK, Miller JJ. A photoaffinity label for the D-1 dopamine receptor, (RS)-7-[125I]Iodo-8-hydroxy-3-methyl-1-(4'-azidophenyl)-2,3,4,5- tetrahydro-1H-3-benzazepine, selectively identifies the ligand binding subunits of the receptor. J Med Chem. 1988 Nov; 31(11):2069-71.
    View in: PubMed
  114. Niznik HB, Jarvie KR, Bzowej NH, Seeman P, Garlick RK, Miller JJ, Baindur N, Neumeyer JL. Photoaffinity labeling of dopamine D1 receptors. Biochemistry. 1988 Oct 4; 27(20):7594-9.
    View in: PubMed
  115. Jacobson KA, de la Cruz R, Schulick R, Kiriasis L, Padgett W, Pfleiderer W, Kirk KL, Neumeyer JL, Daly JW. 8-Substituted xanthines as antagonists at A1- and A2-adenosine receptors. Biochem Pharmacol. 1988 Oct 1; 37(19):3653-61.
    View in: PubMed
  116. Cox RF, Neumeyer JL, Waszczak BL. Effects of N-n-propylnorapomorphine enantiomers on single unit activity of substantia nigra pars compacta and ventral tegmental area dopamine neurons. J Pharmacol Exp Ther. 1988 Oct; 247(1):355-62.
    View in: PubMed
  117. Gao Y, Zong R, Campbell A, Kula NS, Baldessarini RJ, Neumeyer JL. Synthesis and dopamine agonist and antagonist effects of (R)-(-)- and (S)-(+)-11-hydroxy-N-n-propylnoraporphine. J Med Chem. 1988 Jul; 31(7):1392-6.
    View in: PubMed
  118. Lampen P, Neumeyer JL, Baldessarini RJ. High-performance liquid chromatographic separation and electrochemical or spectrophotometric determination of R(-)N-n-propylnorapomorphine and R(-)10,11-methylenedioxy-N-n-propylnoraporphine in primate plasma. J Chromatogr. 1988 Apr 29; 426(2):283-94.
    View in: PubMed
  119. Kula NS, Baldessarini RJ, Murphy F, Neumeyer JL. Substituted phenylpiperidines and phenylpyridines as reversible selective inhibitors of monoamine oxidase type A in rodent brain and liver. Biochem Pharmacol. 1988 Feb 15; 37(4):763-6.
    View in: PubMed
  120. Neumeyer JL, Froimowitz M, Baldessarini RJ, Campbell A, Gao YG. Neuropharmacology and stereochemistry of dopamine receptor agonist and antagonist enantiomeric pairs. J Recept Res. 1988; 8(1-4):83-96.
    View in: PubMed
  121. Campbell A, Baldessarini RJ, Kula NS, Ram VJ, Neumeyer JL. S(+)methylenedioxy-N-n-propylnoraporphine: an orally active inhibitor of dopamine selective for rat limbic system. Brain Res. 1987 Feb 17; 403(2):393-7.
    View in: PubMed
  122. Baldessarini RJ, Kula NS, Francoeur D, Finklestein SP, Murphy F, Neumeyer JL. Synthetic analgesics and other phenylpiperidines: effects on uptake and storage of dopamine and other monoamines mouse forebrain tissue. Life Sci. 1986 Nov 10; 39(19):1765-77.
    View in: PubMed
  123. Froimowitz M, Neumeyer JL, Baldessarini RJ. A stereochemical explanation of the dopamine agonist and antagonist activity of stereoisomeric pairs. J Med Chem. 1986 Sep; 29(9):1570-3.
    View in: PubMed
  124. Neumeyer JL, Abdel-Maksoud HM, Trainor TM, Vouros P, Davis PJ. Aporphines 65: chemical, microbial synthesis and characterization by gas chromatography/mass spectrometry of (R)-(-)-10-hydroxy 11-methoxy-N-n-propylnoraporphine, a potential metabolite of N-n-propylnorapomorphine. Biomed Environ Mass Spectrom. 1986 May; 13(5):223-9.
    View in: PubMed
  125. Baldessarini RJ, Neumeyer JL. Lack of depletion of striatal dopamine by phenylpiperidine analgesics. N Engl J Med. 1986 Mar 6; 314(10):649.
    View in: PubMed
  126. Neumeyer JL, Szabo S. Evidence for the involvement of dopamine agonists and antagonists in duodenal ulcer disease. Klin Wochenschr. 1986; 64 Suppl 7:123-7.
    View in: PubMed
  127. Campbell A, Baldessarini RJ, Teicher MH, Neumeyer JL. Behavioral effects of apomorphine isomers in the rat: selective locomotor-inhibitory effects of S(+)N-n-propylnorapomorphine. Psychopharmacology (Berl). 1986; 88(2):158-64.
    View in: PubMed
  128. Szabo S, Brown A, Pihan G, Dali H, Neumeyer JL. Duodenal ulcer induced by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). Proc Soc Exp Biol Med. 1985 Dec; 180(3):567-71.
    View in: PubMed
  129. Seeman P, Watanabe M, Grigoriadis D, Tedesco JL, George SR, Svensson U, Nilsson JL, Neumeyer JL. Dopamine D2 receptor binding sites for agonists. A tetrahedral model. Mol Pharmacol. 1985 Nov; 28(5):391-9.
    View in: PubMed
  130. Kula NS, Baldessarini RJ, Bromley S, Neumeyer JL. Effects of isomers of apomorphines on dopamine receptors in striatal and limbic tissue of rat brain. Life Sci. 1985 Sep 16; 37(11):1051-7.
    View in: PubMed
  131. Campbell A, Baldessarini RJ, Teicher MH, Neumeyer JL. S(+)Apomorphines. Selective inhibition of excitatory effects of dopamine injected into the limbic system of the rat. Neuropharmacology. 1985 May; 24(5):391-9.
    View in: PubMed
  132. Niznik HB, Dumbrille-Ross A, Guan JH, Neumeyer JL, Seeman P. Dopamine D2 receptors photolabeled by iodo-azido-clebopride. Neurosci Lett. 1985 Apr 19; 55(3):267-72.
    View in: PubMed
  133. Neumeyer JL, Guan JH, Niznik HB, Dumbrille-Ross A, Seeman P, Padmanabhan S, Elmaleh DR. Novel photoaffinity label for the dopamine D2 receptor: synthesis of 4-azido-5-iodo-2-methoxy-N-[1-(phenylmethyl)-4-piperidinyl] benzamide (iodoazidoclebopride, IAC) and the corresponding 125I-labeled analogue (125IAC). J Med Chem. 1985 Apr; 28(4):405-7.
    View in: PubMed
  134. Davis PJ, Abdel-Maksoud H, Trainor TM, Vouros P, Neumeyer JL. Stereospecific microbiological 10-O-demethylation of R-(-)-10,11-dimethoxyaporphines. Biochem Biophys Res Commun. 1985 Mar 15; 127(2):407-12.
    View in: PubMed
  135. Niznik HB, Guan JH, Neumeyer JL, Seeman P. A photoaffinity ligand for dopamine D2 receptors: azidoclebopride. Mol Pharmacol. 1985 Feb; 27(2):193-9.
    View in: PubMed
  136. Hjorth S, Neumeyer JL. Central monoaminergic effects of two aporphine analogues to the putative serotonin-receptor agonist, 8-hydroxy-2-di-n-propylaminotetralin. Neuropharmacology. 1984 Oct; 23(10):1187-90.
    View in: PubMed
  137. Niznik HB, Guan JH, Neumeyer JL, Seeman P. A dopamine D2 receptor photolabel: azidoclebopride. Eur J Pharmacol. 1984 Sep 17; 104(3-4):389-90.
    View in: PubMed
  138. Arana GW, Lamont JS, Baldessarini RJ, Teicher MH, Neumeyer JL, Cohen BM. Binding of [3H]apomorphine to an aporphine binding site as well as to dopamine sites in tissue from bovine caudate nucleus. Neuropharmacology. 1984 Aug; 23(8):885-92.
    View in: PubMed
  139. Kula NS, Baldessarini RJ, Campbell A, Finklestein S, Ram VJ, Neumeyer JL. Effects of N-substituted phenyltetrahydropyridines on cerebral high-affinity synaptosomal uptake of dopamine and other monoamines in several mammalian species. Life Sci. 1984 Jun 25; 34(26):2567-75.
    View in: PubMed
  140. Guan JH, Neumeyer JL, Filer CN, Ahern DG, Lilly L, Watanabe M, Grigoriadis D, Seeman P. Aporphines. 58. N-(2-chloroethyl) [8,9-2H]norapomorphine, an irreversible ligand for dopamine receptors: synthesis and application. J Med Chem. 1984 Jun; 27(6):806-10.
    View in: PubMed
  141. Schmidt M, Imbs JL, Neumeyer JL, Giesen EM, Schwartz J. Vascular effects of apomorphine and related compounds in the perfused rat kidney. Eur J Pharmacol. 1984 Jan 13; 97(1-2):75-85.
    View in: PubMed
  142. Arana GW, Baldessarini RJ, Lamont JS, Amlicke D, Neumeyer JL. Pharmacology of high-affinity binding of [3H](+/-)2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN) to bovine caudate nucleus tissue. Biochem Pharmacol. 1983 Oct 1; 32(19):2873-80.
    View in: PubMed
  143. Cohen SA, Neumeyer JL. Aporphines. 50. Kinetics of solvolysis of N-(2-chloroethyl)norapomorphine, an irreversible dopamine receptor antagonist. J Med Chem. 1983 Oct; 26(10):1348-53.
    View in: PubMed
  144. Bradbury AJ, Costall B, Naylor RJ, Neumeyer JL. Motor inhibition induced by aporphine derivatives in the mouse. J Pharm Pharmacol. 1983 Aug; 35(8):494-9.
    View in: PubMed
  145. Maksoud HM, Kuttab SH, Neumeyer JL, Vouros P. Analysis of N-n-propylnorapomorphine in plasma and tissue by capillary gas chromatography--electron-capture detection. J Chromatogr. 1983 May 13; 274:149-59.
    View in: PubMed
  146. Neumeyer JL, Reischig D, Arana GW, Campbell A, Baldessarini RJ, Kula NS, Watling KJ. Aporphines. 48. Enantioselectivity of (R)-(-)- and (S)-(+)-N-n-propylnorapomorphine on dopamine receptors. J Med Chem. 1983 Apr; 26(4):516-21.
    View in: PubMed
  147. Neumeyer JL, Szabo S. (-)-10,11-Methylenedioxy-N-propylnoraporphine, an orally effective dopamine agonist and duodenal antiulcerogen in the rat. Eur J Pharmacol. 1983 Mar 25; 88(2-3):273-4.
    View in: PubMed
  148. Jackson EA, Neumeyer JL, Kelly PH. Behavioral activity of some novel aporphines in rats with 6-hydroxydopamine lesions of caudate or nucleus accumbens. Eur J Pharmacol. 1983 Jan 28; 87(1):15-23.
    View in: PubMed
  149. Anlezark GM, Blackwood DH, Meldrum BS, Ram VJ, Neumeyer JL. Comparative assessment of dopamine agonist aporphines as anticonvulsants in two models of reflex epilepsy. Psychopharmacology (Berl). 1983; 81(2):135-9.
    View in: PubMed
  150. Sperk G, Campbell A, Baldessarini RJ, Stoll A, Neumeyer JL. Tissue levels of N-n-propylnorapomorphine after treatment with (-)10,11-methylenedioxy-N-n-propylnoraporphine, an orally long-acting prodrug active at central dopamine receptors. Neuropharmacology. 1982 Dec; 21(12):1311-6.
    View in: PubMed
  151. Campbell A, Baldessarini RJ, Ram VJ, Neumeyer JL. Behavioral effects of (-)10,11-methylenedioxy-N-n-propylnoraporphine, an orally effective long-acting agent active at central dopamine receptors, and analogous aporphines. Neuropharmacology. 1982 Oct; 21(10):953-61.
    View in: PubMed
  152. Neumeyer JL, Arana GW, Ram VJ, Kula NS, Baldessarini RJ. Aporphines. 39. Synthesis, dopamine receptor binding, and pharmacological activity of (R)-(-)- and (S)-(+)-2-hydroxyapomorphine. J Med Chem. 1982 Aug; 25(8):990-2.
    View in: PubMed
  153. Baldessarini RJ, Neumeyer JL, Campbell A, Sperk G, Ram VJ, Arana GW, Kula NS. An orally effective, long-acting dopaminergic prodrug: (-)-10,11-methylenedioxy-N-propylnoraporphine. Eur J Pharmacol. 1982 Jan 8; 77(1):87-8.
    View in: PubMed
  154. Neumeyer JL, Arana GW, Law SJ, Lamont JS, Kula NS, Baldessarini RJ. Aporphines, 36. Dopamine receptor interactions of trihydroxyaporphines. Synthesis, radioreceptor binding, and striatal adenylate cyclase stimulation of 2,10,11-trihydroxyaporphines in comparison with other hydroxylated aporphines. J Med Chem. 1981 Dec; 24(12):1440-5.
    View in: PubMed
  155. Neumeyer JL, Law SJ, Meldrum B, Anlezark G, Watling KJ. Aporphines. 34. (-)-2,10,11-Trihydroxy-N-n-propylnoraporphine, a novel dopaminergic aporphine alkaloid with anticonvulsant activity. J Med Chem. 1981 Jul; 24(7):898-9.
    View in: PubMed
  156. Baldessarini RJ, Kula NS, Arana GW, Neumeyer JL, Law SJ. Chloroethylnorapomorphine, a proposed long-acting dopamine antagonist: interactions with dopamine receptors of mammalian forebrain in vitro. Eur J Pharmacol. 1980 Oct 3; 67(1):105-10.
    View in: PubMed
  157. Neumeyer JL, Granchelli FE, Filer CN, Soloway AH, Law SJ. Aporphines. 31. Synthesis and antitumor activity of aporphine nitrogen mustards. J Med Chem. 1980 Sep; 23(9):1008-13.
    View in: PubMed
  158. Green JF, Jham GN, Neumeyer JL, Vouros P. Aporphines XXVI: GLC and mass spectrometric properties of trifluoracetyl derivatives of N-methyl-, N-propyl-, and noraporphines. J Pharm Sci. 1980 Aug; 69(8):936-42.
    View in: PubMed
  159. Costall B, Fortune DH, Granchelli FE, Law SJ, Naylor RJ, Neumeyer JL, Nohria V. On the ability of N-chloroethyl aporphine derivatives to cause irreversible inhibition of dopamine receptor mechanisms. J Pharm Pharmacol. 1980 Aug; 32(8):571-6.
    View in: PubMed
  160. Costall B, Fortune DH, Law SJ, Naylor RJ, Neumeyer JL, Nohria V. (-)N-(chloroethyl)norapomorphine inhibits striatal dopamine function via irreversible receptor binding. Nature. 1980 Jun 19; 285(5766):571-3.
    View in: PubMed
  161. Neumeyer JL, Law SJ, Baldessarini RJ, Kula NS. Aporphines. 30. (-)-N(2-chloroethyl)-10,11-dihydroxynor-aporphine (chloroethylnorapomorphine), a novel irreversible dopamine receptor antagonist. J Med Chem. 1980 Jun; 23(6):594-5.
    View in: PubMed
  162. Green JF, Evans JV, Neumeyer JL, Vouros P. Aporphines. 25-trimethylislyl derivatives of N-methyl and N-propyl aporphines: gas chromatographic and mass spectrometric properties. Biomed Mass Spectrom. 1979 Jul; 6(7):282-6.
    View in: PubMed
  163. Menon MK, Clark WG, Neumeyer JL. Comparison of the dopaminergic effects of apomorphine and (-)-N-n-propylnorapomorphine. Eur J Pharmacol. 1978 Nov 1; 52(1):1-9.
    View in: PubMed
  164. Filer CN, Granchelli FE, Soloway AH, Neumeyer JL. Isoquinolines. 6. Potential central nervous system antitumor agents. Nitrogen mustards of 3-amino-4-(p-aminophenyl)isoquinoline. J Med Chem. 1977 Nov; 20(11):1504-8.
    View in: PubMed
  165. Neumeyer JL, Perianayagam C, Ruchirawat S. Isoquinolines. 5. Synthesis and antiarrhythmic activity of benzylisoquinoline derivatives. J Med Chem. 1977 Jul; 20(7):894-8.
    View in: PubMed
  166. Granchelli FE, Soloway AH, Neumeyer JL, Filer CN. Aporphines. 23. normorphothebaine derivatives: synthesis of an aporphine nitrogen mustard. J Org Chem. 1977 May 27; 42(11):2014-7.
    View in: PubMed
  167. Neumeyer JL, Uretsky NJ, Charest RR. Effects of (+/-)-10-hydroxy-N-n-propylnoraporphine on catecholamine turnover in the rat brain. J Pharm Pharmacol. 1977 Mar; 29(3):179-81.
    View in: PubMed
  168. Gottlieb R, Neumeyer JL. Aporphines. 22. Electrochemical synthesis of aporphines via cathodic cyclization of iodobenzylisoquinolinium salts. J Am Chem Soc. 1976 Oct 27; 98(22):7108-9.
    View in: PubMed
  169. Smith RV, Erhardt PW, Neumeyer JL, Borgmen RJ. Metabolism in vitro of potential apomorphine prodrugs. Biochem Pharmacol. 1976 Sep 15; 25(18):2106-7.
    View in: PubMed
  170. Neumeyer JL, Reinhard JF, Dafeldecker WP, Guarino J, Kosersky DS, Fuxe K, Agnati L. Aporphines. 14 Dopaminergic and antinociceptive activity of aporphine derivatives. Synthesis of 10-hydroxyaporphines and 10-hydroxy-N-n-propylnoraporphine. J Med Chem. 1976 Jan; 19(1):25-9.
    View in: PubMed
  171. Kelly PH, Miller RJ, Neumeyer JL. Aporphines. 16. Action of aporphine alkaloids on locomotor activity in rats with 6-hydroxydopamine lesions of the nucleus accumbens. Eur J Pharmacol. 1976 Jan; 35(1):85-92.
    View in: PubMed
  172. Miller RJ, Kelly PH, Neumeyer JL. Aporphines. 15. Action of aporphine alkaloids on dopaminergic mechanisms in rat brain. Eur J Pharmacol. 1976 Jan; 35(1):77-83.
    View in: PubMed
  173. Costall B, Naylor RJ, Neumeyer JL. Dissociation by the aporphine derivatives of the stereotypic and hyperactivity responses resulting from injections into the nucleus accumbens septi. J Pharm Pharmacol. 1975 Nov; 27(11):875-7.
    View in: PubMed
  174. Kelly PH, Miller RJ, Neumeyer JL. Proceedings: Effect of aporphine alkaloids on central dopamine receptors. Br J Pharmacol. 1975 Jun; 54(2):271P.
    View in: PubMed
  175. Costall B, Naylor RJ, Neumeyer JL. Differences in the nature of the stereotyped behaviour induced by aporphine derivatives in the rat and in their actions in extrapyramidal and mesolimbic brain areas. Eur J Pharmacol. 1975 Mar; 31(1):1-16.
    View in: PubMed
  176. Schoenfeld RI, Neumeyer JL, Dafeldecker W, Roffler-Tarlov S. Comparison of structural and stereoisomers of apomorphine on stereotyped behavior of the rat. Eur J Pharmacol. 1975 Jan; 30(1):63-8.
    View in: PubMed
  177. Neumeyer JL, Granchelli FE. Aporphines. 11. Synthesis and dopaminergic acitivity of monohydroxyaporphines. Total synthesis of (plus, minus)-11-hydroxyaporphine, (plus and minus)-11-hydroxynoraporphine, and (plus, minus)-11-hydroxy-N-n-propylnoraporphine. J Med Chem. 1974 Oct; 17(10):1090-5.
    View in: PubMed
  178. Dey AS, Neumeyer JL. Synthesis and antimalarial evaluation of 9,10-dihydrophenanthrene amino alcohols. J Med Chem. 1974 Oct; 17(10):1095-100.
    View in: PubMed
  179. Neumeyer JL, Neustadt BR, Oh KH, Weinhardt KK, Boyce CB, Rosenberg FJ, Teiger DG. Aporphines. 8. Total synthesis and pharmacological evaluation of (plus or minus)-apomorphine, (plus or minus)-apocodeine, (plus or minus)-N-n-propylnorapomorphine, and (plus or minus)-N-n-propylnorapocodeine. J Med Chem. 1973 Nov; 16(11):1223-8.
    View in: PubMed
  180. Neumeyer JL, Weinhardt KK, Carrano RA, McCurdy DH. Isoquinolines. 3. 3-Aminoisoquinoline derivatives with central nervous system depressant activity. J Med Chem. 1973 Jul; 16(7):808-13.
    View in: PubMed
  181. Neumeyer JL, Neustadt BR, Weinhardt KK. Aporphines. V. Total synthesis of (plus or minus)-apomorphine. J Pharm Sci. 1970 Dec; 59(12):1850-2.
    View in: PubMed
  182. Jaffe H, Neumeyer JL. Comparative effects of piperonyl butoxide and N-(4-pentynyl)phthalimide on mammalian microsomal enzyme functions. J Med Chem. 1970 Sep; 13(5):901-3.
    View in: PubMed
  183. Neumeyer JL, Weinhardt KK. Isoquinolines. I. 3-amino- and 3-fluoroisoquinoline derivatives as potential antimalarials. J Med Chem. 1970 Jul; 13(4):613-9.
    View in: PubMed
  184. Neumeyer JL, Ho KH, Weinhardt KK, Neustadt BR. The chemistry of aporphines. IV. Synthesis of aporphines via Reissert alkylation photochemical cyclization, and the Pschorr cyclization route. J Org Chem. 1969 Dec; 34(12):3786-8.
    View in: PubMed
  185. Neumeyer JL, Moyer UV, Leonard JE. Pharmacologically active acetylene compounds. II. Propynyl-substituted indole derivatives. J Med Chem. 1969 May; 12(3):450-2.
    View in: PubMed
  186. Neumeyer JL, Moyer UV, Richman JA, Rosenberg FJ, Teiger DG. Pharmacologically active acetylene compounds. I. Structural modifications of oxotremorine. J Med Chem. 1967 Jul; 10(4):615-20.
    View in: PubMed
  187. NEUMEYER JL, CANNON JG, BUCKLEY JP. SYNTHESIS AND HYPOTENSIVE ACTIVITY OF UNSYMMETRICALLY SUBSTITUTED ACETYLENIC BIS-QUATERNARY AMMONIUM COMPOUNDS AND CERTAIN OF THEIR REDUCTION PRODUCTS. J Med Pharm Chem. 1962 Jul; 91:784-92.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Neumeyer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (469) concept(s)
_
Co-Authors
See all (17) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_